Management decisions made by physician assistants and nurse practitioners in cutaneous malignant melanoma patients: Impact of a 31-gene expression profile test

Rachel S. Mirsky, Giselle Prado, Ryan M. Svoboda, Alex M. Glazer, Darrell S. Rigel

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Importance: The 31 gene-expression profiling test (31-GEP) has been shown to provide useful prognostic information in patients with cutaneous melanoma. The test dichotomizes patients into lower risk (Class 1) or higher risk (Class 2) for melanoma metastasis. Previous studies have demonstrated the clinical utility of the test in impacting dermatologists’ management decisions. Physician assistants and nurse practitioners (PA/NPs) account for a significant portion of dermatologic providers. The impact of a 31-GEP assay on clinical management has not been evaluated in this group. Objective: To determine the impact of 31-GEP test results on management decisions made by dermatology PA/NPs for cutaneous melanoma patients. Design, Setting, and Participants: 164 PA/NPs attending a national dermatology conference completed an online survey designed to determine the impact of 31-GEP test results on management decisions in a variety of clinical situations. Participants answered a series of questions related to six melanoma patient vignettes, each featuring different patient and lesion characteristics. Main Outcomes and Measures: Proportion of PA/NPs who would recommend sentinel lymph node biopsy (SLNBx) or further imaging for each patient vignette (without 31-GEP results, with a lower risk result, or with a higher risk result). The effect of the test results on the follow-up intervals recommended by PA/NPs was also examined. Results: who ment would toward In the recommend increased majority intensity of SLNBx, cases (more imaging, a lower recommendations risk or quarterly Do 31-GEP test follow-up. Not for result SLNBx Conversely, led to imaging, Copy a statistically a higher or quarterly significant risk 31-GEP follow-up) decrease result in all significantly in cases. the proportion altered of manage- PA/NPs Conclusions PA/NPs regarding and SLNBx Relevance: acquisition The results of imaging of Penalties a 31-GEP and follow-up test appear for to patients significantly Apply with cutaneous impact management melanoma.

Original languageEnglish
Pages (from-to)1220-1223
Number of pages4
JournalJournal of Drugs in Dermatology
Volume17
Issue number11
StatePublished - Nov 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'Management decisions made by physician assistants and nurse practitioners in cutaneous malignant melanoma patients: Impact of a 31-gene expression profile test'. Together they form a unique fingerprint.

Cite this